28 July 2017 - The TGA is seeking comments from interested parties on proposed options on whether there is a need in Australia for additional naming requirements for biological medicines as a way of strengthening traceability and pharmacovigilance.

Government is committed to implementing a biosimilar medicines uptake policy. Biosimilar medicines provide an opportunity to reduce the cost to Government of subsidising expensive biological medicines. The Biosimilar Awareness Initiative was announced in May 2015. The aim of the Initiative is to support awareness of, and confidence in, the use of biosimilar medicines for healthcare professionals and consumers.

Read TGA news article